Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclic adenosine monophosphate-Protein kinase A-cAMP response element-binding protein-Brain-derived neurotrophic factor (cAMP-PKA-CREB-BDNF) signaling pathway is a fundamental intracellular cascade that regulates synaptic plasticity, neuronal survival, and cognitive function (Pittenger & Duman, 2008; PubMed: 18708142). The process is initiated by the production of the second messenger cAMP, which activates Protein Kinase A (PKA). Activated PKA then phosphorylates the transcription factor cAMP Response Element-Binding protein (CREB), which binds to promoter regions to drive the expression of neurotrophic factors, most notably Brain-Derived Neurotrophic Factor (BDNF) (Carlezon et al., 2005; PubMed: 15694330). BDNF plays a pivotal role in the maintenance of existing neurons and the growth of new synapses, making this pathway a central focus in neuropsychiatric research (Lu et al., 2013; PubMed: 23696251). Dysregulation of this axis is implicated in the pathogenesis of depression and various neurodegenerative conditions, where reduced BDNF levels are often observed (Dwivedi, 2009; PubMed: 19359672). Consequently, therapeutic strategies aimed at enhancing this pathway—such as phosphodiesterase inhibitors or direct receptor agonists—are being explored to treat mood disorders and cognitive decline (Zhang et al., 2018; PubMed: 29486312).
Enhancement of this pathway is typically achieved by increasing intracellular cAMP levels through adenylate cyclase activation or phosphodiesterase (PDE) inhibition. Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates the transcription factor CREB at Ser133. Phosphorylated CREB then binds to cAMP response elements (CRE) in the promoter region of the BDNF gene, inducing its transcription and subsequent protein synthesis to promote neuronal health and synaptic connectivity (StatPearls, 2023; NBK470256; Nibuya et al., 1996; PubMed: 8630702).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic adenosine monophosphate-Protein kinase A-cAMP response element-binding protein-Brain-derived neurotrophic factor signaling pathway (cAMP-PKA-CREB-BDNF) (cAMP-PKA-CREB-BDNF).